首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1895164

基因修飾療法的臨床應用：基因療法、基因修飾細胞療法、RNA療法、基因編輯

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

出版日期: 2025年12月30日 | 出版商:

BCC Research | 英文 166 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球基因修飾療法市場預計將從2025年的148億美元成長到2030年底的321億美元，2025年至2030年的年複合成長率為 16.8%。

預計北美基因修飾療法市場將從2025年的73億美元成長到2030年底的164億美元，2025年至2030年的年複合成長率為 17.7%。

歐洲基因修飾療法市場預計將從2025年的41億美元成長到2030年底的86億美元，2025年至2030年的年複合成長率為 16.3%。

本報告調查了全球基因修飾療法市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

市場動態
市場促進因素
罕見遺傳疾病盛行率不斷上升
人們越來越關注精準醫療
市場限制
不利事件追蹤和長期監測的監管要求
基因組編輯科技的倫理問題
基因修飾療法的高成本
市場機會
拓展基因修飾療法的應用領域
基因修飾細胞療法中的現成產品

第5章新興技術與管道分析

重點總結
新興技術
CRISPR的體內遞送
改進的Cas變體
RNAi遞送系統的進展
RNA編輯
管道分析
RNA療法
基因編輯療法
基因療法與基因修飾細胞療法

第6章市場區隔分析

細分市場分析
平台技術市場分析
重點總結
RNA療法
基因改造細胞療法
基因治療
基因編輯
市場分析：依應用領域
重點總結
瘤
罕見疾病
心血管疾病
肌肉骨骼疾病
血液疾病
其他
地理細分
市場分析：依地區
重點總結
北美洲
歐洲
亞太地區
其他地區

第7章競爭訊息

重點總結
產業結構
RNA療法企業市場占有率分析
基因治療市場企業市場占有率分析
基因修飾細胞療法市場企業市場占有率分析
戰略分析

第8章基因修飾療法市場的永續性：ESG視角

ESG簡介
ESG風險評估
結論

第9章附錄

調查方法
來源
簡稱
公司簡介
ALNYLAM PHARMACEUTICALS INC.
AMGEN INC.
BIOGEN
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
FERRING
GENETIX BIOTHERAPEUTICS INC.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
LILLY USA LLC.
NOVARTIS AG
NOVO NORDISK A/S
SANOFI
SAREPTA THERAPEUTICS INC.
VERTEX PHARMACEUTICALS INC.
新興Start-Ups/市場顛覆者

簡介目錄圖表

Product Code: BIO159B

The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.

The North American market for genetic modification therapies is estimated to grow from $7.3 billion in 2025 to reach $16.4 billion by the end of 2030, at a CAGR of 17.7% from 2025 through 2030.

The European market for genetic modification therapies is estimated to grow from $4.1 billion in 2025 to reach $8.6 billion by the end of 2030, at a CAGR of 16.3% from 2025 through 2030.

Report Scope

The report provides an overview of genetic modification therapies clinical applications: gene therapies, genetically modified cell therapies, RNA therapies and gene editing market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. In this report, the market is segmented based on platform technology, application and region.

Based on platform technology, the market is segmented into gene editing, gene therapy, gene-modified cell therapy and RNA therapy platforms. The application segment covers oncology, rare diseases, cardiovascular diseases, musculoskeletal conditions, hematological disorders and other applications. The gene therapy segment is segmented based on the delivery systems into adeno-associated virus (AAV), herpes simplex virus (HSV)-1, lentivirus and others. The RNA therapy segment is segmented into antisense oligonucleotides, small interfering RNAs and others based on type.

The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, Asia-Pacific, and the Rest of the World, with a focus on major countries in these regions.

The report also includes major driving trends and restraints that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments, discussing pipeline activities and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also has a dedicated section of company profiles that covers details of leading companies. The report does not include mRNA vaccines.

Report Includes

103 data tables and 63 additional tables
Overview and an analysis of the global market for clinical applications of genetic modification therapies
In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
Evaluation of the current market size and revenue growth prospects specific to the genetic modification therapies, accompanied by a market share analysis by platform technology, application and region
Analysis of current and future demand in the genetic modification therapies, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
Review of gene editing, gene therapy, CAR T-cell therapy, RNA therapy and lentiviral production, and discussion of how they are playing a key role in genetic modification therapies
Analysis of drivers, challenges and opportunities affecting market growth
Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
Market share analysis of the key market participants of the industry, along with their research priorities, product portfolios, global rankings and competitive landscape
Profiles of the leading companies, including Gilead Sciences Inc., Alnylam Pharmaceuticals Inc., Novartis AG, Bristol-Myers Squibb Co., and Sarepta Therapeutics Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Overview
Porter's Five Forces Analysis
Threat of New Entrants (Low)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Moderate)
Threat of Substitute (Low)
Industry Rivalry (High)
Macroeconomic Factors Analysis
Impact of the U.S. Tariffs
Geopolitical Factors

Chapter 3 Genetic Modification Therapies: Technology and Applications

Genetic Modification Therapies
Gene Therapy Technologies
RNA Therapy Technologies
Gene Editing Technologies
Different Types of Genome Editing Tools
Delivery Methods of Genome Editing
Gene-Modified Cell Therapy Technologies
Delivery Technologies
Clinical Applications

Chapter 4 Market Dynamics

Market Dynamics
Market Drivers
Increasing Prevalence of Rare Genetic Disorders
Growing Focus on Precision Medicine
Market Restraints
Regulatory Requirements on Adverse Event Tracking and Long-Term Monitoring
Ethical Concerns on Genome Editing Techniques
High Cost of Genetic Modification Therapies
Market Opportunities
Expanding Application Areas of Genetic Modification Therapies
Off-the-Shelf Products in Gene-Modified Cell Therapies

Chapter 5 Emerging Technologies and Pipeline Analysis

Key Takeaways
Emerging Technologies
In Vivo Delivery of CRISPR
Improved Cas Variants
Advances in RNAi Delivery Systems
RNA Editing
Pipeline Analysis
RNA Therapies
Gene Editing Therapies
Gene Therapies and Gene-Modified Cell Therapies

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Market Analysis by Platform Technology
Key Takeaways
RNA Therapy
Gene-Modified Cell Therapy
Gene Therapy
Gene Editing
Market Analysis by Application
Key Takeaways
Oncology
Rare Diseases
Cardiovascular Diseases
Musculoskeletal Conditions
Hematological Disorders
Others
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Key Takeaways
Industry Structure
Company Share Analysis of the RNA Therapies Market
Company Share Analysis of the Gene Therapies Market
Company Share Analysis of the Gene-Modified Cell Therapies Market
Strategic Analysis

Chapter 8 Sustainability in the Genetic Modification Therapies Market: An ESG Perspective

Introduction to ESG
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ALNYLAM PHARMACEUTICALS INC.
AMGEN INC.
BIOGEN
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
FERRING
GENETIX BIOTHERAPEUTICS INC.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
LILLY USA LLC.
NOVARTIS AG
NOVO NORDISK A/S
SANOFI
SAREPTA THERAPEUTICS INC.
VERTEX PHARMACEUTICALS INC.
Emerging Startups/Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Genetic Modification Therapies, by Region, Through 2030
Table 1 : Genetic Modification Platforms
Table 2 : Comparison of Traditional Pharmaceuticals and Genetic Modification Therapies
Table 3 : Distinct Features of the Genetic Modification Approaches
Table 4 : Comparison of Genome Editing Tools
Table 5 : Gene-Modified Cell Therapy Technologies
Table 6 : Applications of Genetic Modification Therapies
Table 7 : List of Selected Pipeline Molecules
Table 8 : List of Gene Editing Therapeutic Trials in Phase I
Table 9 : List of Gene Editing Therapeutic Trials in Phase I/II, II and III
Table 10 : List of Selected Pipeline Molecules
Table 11 : Global Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 12 : Global Market for RNA Therapy, by Region, Through 2030
Table 13 : Global Market for RNA Therapy, by RNA Type, Through 2030
Table 14 : Global Market for Antisense Oligonucleotides, by Region, Through 2030
Table 15 : RNAi Approved Drugs List
Table 16 : Global Market for Small Interfering RNAs, by Region, Through 2030
Table 17 : Global Market for Other RNA-Based Therapeutics, by Region, Through 2030
Table 18 : Approved CAR T-Cell Therapies
Table 19 : Global Market for Gene-Modified Cell Therapy, by Region, Through 2030
Table 20 : Global Market for Gene Therapy, by Region, Through 2030
Table 21 : Global Market for Gene Therapy, by Delivery System, Through 2030
Table 22 : Global Market for AAV Delivery System in Gene Therapy, by Region, Through 2030
Table 23 : Global Market for HSV-1 Delivery System in Gene Therapy, by Region, Through 2030
Table 24 : Global Market for Lentivirus Delivery System in Gene Therapy, by Region, Through 2030
Table 25 : Global Market for Other Delivery Systems in Gene Therapy, by Region, Through 2030
Table 26 : Global Market for Gene Editing Therapy, by Region, Through 2030
Table 27 : Global Market for Genetic Modification Therapies, by Application, Through 2030
Table 28 : Global Market for Genetic Modification Therapies for Oncology, by Region, Through 2030
Table 29 : Global Market for Genetic Modification Therapies for Rare Diseases, by Region, Through 2030
Table 30 : Global Market for Genetic Modification Therapies for Cardiovascular Diseases, by Region, Through 2030
Table 31 : Global Market for Genetic Modification Therapies for Musculoskeletal Conditions, by Region, Through 2030
Table 32 : Global Market for Genetic Modification Therapies for Hematological Disorders, by Region, Through 2030
Table 33 : Global Market for Genetic Modification Therapies for Other Applications, by Region, Through 2030
Table 34 : Global Market for Genetic Modification Therapies, by Region, Through 2030
Table 35 : North American Market for Genetic Modification Therapies, by Country, Through 2030
Table 36 : North American Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 37 : North American Market for Gene Therapy, by Delivery System, Through 2030
Table 38 : North American Market for RNA Therapy, by RNA Type, Through 2030
Table 39 : North American Market for Genetic Modification Therapies, by Application, Through 2030
Table 40 : U.S. Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 41 : U.S. Market for Gene Therapy, by Delivery System, Through 2030
Table 42 : U.S. Market for Genetic Modification Therapies, by Application, Through 2030
Table 43 : Canadian Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 44 : Canadian Market for Gene Therapy, by Delivery System, Through 2030
Table 45 : Canadian Market for Genetic Modification Therapies, by Application, Through 2030
Table 46 : Mexican Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 47 : Mexican Market for Gene Therapy, by Delivery System, Through 2030
Table 48 : Mexican Market for Genetic Modification Therapies, by Application, Through 2030
Table 49 : European Market for Genetic Modification Therapies, by Country, Through 2030
Table 50 : European Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 51 : European Market for Gene Therapy, by Delivery System, Through 2030
Table 52 : European Market for RNA Therapy, by RNA Type, Through 2030
Table 53 : European Market for Genetic Modification Therapies, by Application, Through 2030
Table 54 : German Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 55 : German Market for Gene Therapy, by Delivery System, Through 2030
Table 56 : German Market for Genetic Modification Therapies, by Application, Through 2030
Table 57 : U.K. Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 58 : U.K. Market for Gene Therapy, by Delivery System, Through 2030
Table 59 : U.K. Market for Genetic Modification Therapies, by Application, Through 2030
Table 60 : French Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 61 : French Market for Gene Therapy, by Delivery System, Through 2030
Table 62 : French Market for Genetic Modification Therapies, by Application, Through 2030
Table 63 : Italian Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 64 : Italian Market for Gene Therapy, by Delivery System, Through 2030
Table 65 : Italian Market for Genetic Modification Therapies, by Application, Through 2030
Table 66 : Spanish Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 67 : Spanish Market for Gene Therapy, by Delivery System, Through 2030
Table 68 : Spanish Market for Genetic Modification Therapies, by Application, Through 2030
Table 69 : Rest of Europe Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 70 : Rest of Europe Market for Gene Therapy, by Delivery System, Through 2030
Table 71 : Rest of Europe Market for Genetic Modification Therapies, by Application, Through 2030
Table 72 : Asia-Pacific Market for Genetic Modification Therapies, by Country, Through 2030
Table 73 : Asia-Pacific Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 74 : Asia-Pacific Market for Gene Therapy, by Delivery System, Through 2030
Table 75 : Asia-Pacific Market for RNA Therapy, by RNA Type, Through 2030
Table 76 : Asia-Pacific Market for Genetic Modification Therapies, by Application, Through 2030
Table 77 : Chinese Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 78 : Chinese Market for Gene Therapy, by Delivery System, Through 2030
Table 79 : Chinese Market for Genetic Modification Therapies, by Application, Through 2030
Table 80 : Japanese Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 81 : Japanese Market for Gene Therapy, by Delivery System, Through 2030
Table 82 : Japanese Market for Genetic Modification Therapies, by Application, Through 2030
Table 83 : South Korean Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 84 : South Korean Market for Gene Therapy, by Delivery System, Through 2030
Table 85 : South Korean Market for Genetic Modification Therapies, by Application, Through 2030
Table 86 : Indian Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 87 : Indian Market for Gene Therapy, by Delivery System, Through 2030
Table 88 : Indian Market for Genetic Modification Therapies, by Application, Through 2030
Table 89 : Australian Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 90 : Australian Market for Gene Therapy, by Delivery System, Through 2030
Table 91 : Australian Market for Genetic Modification Therapies, by Application, Through 2030
Table 92 : Rest of Asia-Pacific Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 93 : Rest of Asia-Pacific Market for Gene Therapy, by Delivery System, Through 2030
Table 94 : Rest of Asia-Pacific Market for Genetic Modification Therapies, by Application, Through 2030
Table 95 : RoW Market for Genetic Modification Therapies, by Subregion, Through 2030
Table 96 : RoW Market for Genetic Modification Therapies, by Platform Technology, Through 2030
Table 97 : RoW Market for Gene Therapy, by Delivery System, Through 2030
Table 98 : RoW Market for RNA Therapy, by RNA Type, Through 2030
Table 99 : RoW Market for Genetic Modification Therapies, by Application, Through 2030
Table 100 : Recent Developments in the Genetic Modification Therapies Market, 2022-2025
Table 101 : Key Focus Areas in ESG Metrics
Table 102 : ESG Risk Rankings for Genetic Modification Therapies Companies, 2025
Table 103 : Report Information Sources
Table 104 : Abbreviations Used in the Global Genetic Modification Therapies Market
Table 105 : Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 106 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 107 : Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 108 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 109 : Amgen Inc.: Company Snapshot
Table 110 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 111 : Amgen Inc.: Product Portfolio
Table 112 : Amgen Inc.: News/Key Developments, 2022-2025
Table 113 : Biogen: Company Snapshot
Table 114 : Biogen: Financial Performance, FY 2023 and 2024
Table 115 : Biogen: Product Portfolio
Table 116 : Biogen: News/Recent Developments, 2022
Table 117 : Bristol-Myers Squibb Co.: Company Snapshot
Table 118 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 119 : Bristol-Myers Squibb Co.: Product Portfolio
Table 120 : Bristol-Myers Squibb Co.: News/Key Developments, 2025
Table 121 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 122 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 123 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 124 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 125 : Ferring: Company Snapshot
Table 126 : Ferring: Financial Performance, FY 2023 and 2024
Table 127 : Ferring: Product Portfolio
Table 128 : Ferring: News/Key Developments, 2023-2024
Table 129 : Genetix Biotherapeutics Inc.: Company Snapshot
Table 130 : Genetix Biotherapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 131 : Genetix Biotherapeutics Inc.: Product Portfolio
Table 132 : Genetix Biotherapeutics Inc.: News/Key Developments, 2025
Table 133 : Gilead Sciences Inc.: Company Snapshot
Table 134 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 135 : Gilead Sciences Inc.: Product Portfolio
Table 136 : Gilead Sciences Inc.: News/Key Developments, 2023-2024
Table 137 : Johnson & Johnson: Company Snapshot
Table 138 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 139 : Johnson & Johnson: Product Portfolio
Table 140 : Johnson & Johnson: News/Key Developments, 2024
Table 141 : Lilly USA LLC.: Company Snapshot
Table 142 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 143 : Lilly USA LLC.: Product Portfolio
Table 144 : Lilly USA LLC.: News/Key Developments, 2025
Table 145 : Novartis AG: Company Snapshot
Table 146 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 147 : Novartis AG: Product Portfolio
Table 148 : Novartis AG: News/Key Developments, 2023-2025
Table 149 : Novo Nordisk A/S: Company Snapshot
Table 150 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 151 : Novo Nordisk A/S: Product Portfolio
Table 152 : Novo Nordisk A/S: News/Key Developments, 2023-2025
Table 153 : Sanofi: Company Snapshot
Table 154 : Sanofi: Financial Performance, FY 2023 and 2024
Table 155 : Sanofi: Product Portfolio
Table 156 : Sanofi: News/Key Developments, 2024
Table 157 : Sarepta Therapeutics Inc.: Company Snapshot
Table 158 : Sarepta Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 159 : Sarepta Therapeutics Inc.: Product Portfolio
Table 160 : Sarepta Therapeutics Inc.: News/Key Developments, 2024
Table 161 : Vertex Pharmaceuticals Inc.: Company Snapshot
Table 162 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 163 : Vertex Pharmaceuticals Inc.: Product Portfolio
Table 164 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2023-2024
Table 165 : List of a Few Emerging Startups

List of Figures

Summary Figure : Global Market Shares for Genetic Modification Therapies, by Region, 2024
Figure 1 : Porter's Five Forces Analysis: Genetic Modification Therapies Market
Figure 2 : Delivery Systems for Gene Therapy and Gene-Modified Cell Therapy
Figure 3 : Global Market Dynamics of Genetic Modification Therapies
Figure 4 : Emerging Technologies in the Genetic Modification Therapies Market
Figure 5 : Market Shares for Genome Editing Clinical Trials, by Technology, 2009-2024
Figure 6 : Market Shares for Genome Editing Clinical Trials, by Diseases, 2009-2024
Figure 7 : Global Market Shares for Genetic Modification Therapies, by Platform Technology, 2024
Figure 8 : Global Market Shares for RNA Therapy, by RNA Type, 2024
Figure 9 : Global Market Shares for Gene Therapy, by Delivery System, 2024
Figure 10 : Global Market Shares for Genetic Modification Therapies, by Application, 2024
Figure 11 : Global Market Shares for Genetic Modification Therapies, by Region, 2024
Figure 12 : North American Market Shares for Genetic Modification Therapies, by Country, 2024
Figure 13 : European Market Shares for Genetic Modification Therapies, by Country, 2024
Figure 14 : Asia-Pacific Market Shares for Genetic Modification Therapies, by Country, 2024
Figure 15 : RoW Market Shares for Genetic Modification Therapies, by Subregion, 2024
Figure 16 : Global Market Shares for RNA Therapies, by Company, 2024
Figure 17 : Global Market Shares for Gene Therapies, by Company, 2024
Figure 18 : Global Market Shares for Gene-Modified Cell Therapies, by Company, 2024
Figure 19 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 20 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 21 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 22 : Biogen: Revenue Share, by Country/Region, FY 2024
Figure 23 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 24 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 25 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 26 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 27 : Ferring: Revenue Share, by Business Unit, FY 2024
Figure 28 : Ferring: Revenue Share, by Country/Region, FY 2024
Figure 29 : Genetix Biotherapeutics Inc.: Revenue Share, by Business Unit, FY 2024
Figure 30 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 32 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
Figure 33 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
Figure 34 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 35 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 36 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 37 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 38 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2024
Figure 39 : Sanofi: Revenue Share, by Country/Region, FY 2024
Figure 40 : Sarepta Therapeutics Inc.: Revenue Share, by Country/Region, FY 2024
Figure 41 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 42 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024